3rd Therapeutics Discovery
Convention Center, KSAU-HS. 13-15 September, 2022
2022-09-13 03:00:00
Registration
Abstract Submission
  • ABSTRACT SUBMISSION
  • Home
  • About
    • OBJECTIVES
    • EXECUTIVE DIRECTOR MESSAGE
    • CONFERENCE CHAIRMAN MESSAGE
    • CONTACT US
  • SPEAKERS
    • SPEAKER LIST
    • MEET THE EXPERTS
  • PROGRAM
    • CONFERENCE PROGRAM
    • PRE-CONFERENCE WORKHOPS
  • EVENT DETAILS
    • REGISTERATION
      • ATTEND THE CONFERENCE
    • ABSTRACT SUBMISSION
      • ABSTRACT SUBMISSION
    • CONFERENCE DETAILS
      • ORGANIZERS
    • POSTERS
      • EVENT POSTER
      • POSTER TEMPLATE
      • POSTER GUIDELINES
      • POSTER REVIEW PANEL
    • CME
      • CME
  • Home
  • About
    • OBJECTIVES
    • EXECUTIVE DIRECTOR MESSAGE
    • CONFERENCE CHAIRMAN MESSAGE
    • CONTACT US
  • SPEAKERS
    • SPEAKER LIST
    • MEET THE EXPERTS
  • PROGRAM
    • CONFERENCE PROGRAM
    • PRE-CONFERENCE WORKHOPS
  • EVENT DETAILS
    • REGISTERATION
      • ATTEND THE CONFERENCE
    • ABSTRACT SUBMISSION
      • ABSTRACT SUBMISSION
    • CONFERENCE DETAILS
      • ORGANIZERS
    • POSTERS
      • EVENT POSTER
      • POSTER TEMPLATE
      • POSTER GUIDELINES
      • POSTER REVIEW PANEL
    • CME
      • CME
Romee

Prof. Rizwan Romee

Associate Professor of Medicine; Harvard Medical School, Dana Farber Cancer Institute; Boston, MA 02215


Dr. Rizwan Romee is an associate professor of medicine at Harvard Medical School and director of the haploidentical donor transplant program at Dana Farber Cancer Institute (DFCI), Boston. He is also the principal investigator of the Romee Lab for NK Cell Gene Manipulation and Therapy at DFCI. The research focus of his laboratory is genetic manipulation of the human Natural Killer (NK) cells to enhance their anti-tumor function and simultaneously modulate the highly immune suppressive tumor microenvironment (TME). His work at Washington University helped describe human memory-like NK cells with enhanced anti-tumor activity and he led a first in human clinical trial of these cells in patients with relapsed and refractory AML demonstrating safety and promising activity. He is currently leading translational NK cell program at DFCI evaluating memory-like NK cells in combination with novel immune-modulatory agents in patients with advanced malignancies including AML and MDS relapsed after stem cell transplantation, MRD+ multiple myeloma (in combination with CD38 ARM) and head and neck cancer (in combination with CTLA-4 blockade/ipilimumab and IL-15 super-agonist).

Therapeutics Discovery. 13-14-15 September 2022

Contact us

Contacts
KSAU-HS, Al Hars Al Watani, Ar Rimayah Riyadh 14611 Saudi Arabia
KAIMRC-Therapeutics@ngha.med.sa
LINKS
  • Therapeutics Discovery Conference
  • Objectives
  • About Therapeutics Discovery Conference
© 2021 KAIMRC - Advance Computing & Technologies, All Rights Reserved.